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Abstract
Background: Two evolutionarily Conserved Sequence Elements, CSE1 and CSE2 (YY1 binding
sites), are found within the 3.8-kb CpG island surrounding the bidirectional promoter of two
imprinted genes, Peg3 (Paternally expressed gene 3) and Usp29 (Ubiquitin-specific protease 29).
This CpG island is a likely ICR (Imprinting Control Region) that controls transcription of the 500kb genomic region of the Peg3 imprinted domain.
Results: The current study investigated the functional roles of CSE1 and CSE2 in the
transcriptional control of the two genes, Peg3 and Usp29, using cell line-based promoter assays.
The mutation of 6 YY1 binding sites (CSE2) reduced the transcriptional activity of the bidirectional
promoter in the Peg3 direction in an orientation-dependent manner, suggesting an activator role
for CSE2 (YY1 binding sites). However, the activity in the Usp29 direction was not detectable
regardless of the presence/absence of YY1 binding sites. In contrast, mutation of CSE1 increased
the transcriptional activity of the promoter in both the Peg3 and Usp29 directions, suggesting a
potential repressor role for CSE1. The observed repression by CSE1 was also orientationdependent. Serial mutational analyses further narrowed down two separate 6-bp-long regions
within the 42-bp-long CSE1 which are individually responsible for the repression of Peg3 and Usp29.
Conclusion: CSE2 (YY1 binding sites) functions as an activator for Peg3 transcription, while CSE1
acts as a repressor for the transcription of both Peg3 and Usp29.

Background
Peg3 was the first imprinted gene to be identified in proximal mouse chromosome 7, and encodes a C2H2-type
zinc finger protein, which is predicted to be a DNA-binding transcription factor [1]. The expression of Peg3 is ubiquitous, spatially and temporarily, but exhibits very high
levels in the neuronal and germ cells of both mouse and
human [2,3]. Consistently, Peg3 has been shown to be
involved in controlling nurturing behaviors and fetal
growth rates [4]. Independent studies also indicated that

human PEG3 might be a downstream gene for the p53mediated apoptosis pathway [5,6]. Usp29 is another
imprinted gene that is located right next to Peg3 in a headto-head orientation [3]. The physiological role of Usp29 is
currently unknown, but it is believed to be involved in the
ubiquitin-mediated protein degradation pathway.
According to previous studies, Usp29 is also expressed
highly in mouse brains but much lower levels than Peg3
[3]. The overall spatial expression patterns of Usp29 are
similar to those of Peg3. The transcription start sites (TSSs)
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for Peg3 and Usp29 are located very close to each other,
150 bp apart, and thus a genomic region surrounding the
two TSSs is thought to function as a bidirectional promoter for Peg3 and Usp29. A broader genomic region, 3.8
kb in length, surrounding the two TSSs is a CpG island
displaying allele-specific DNA methylation. The maternal
allele of this region is methylated while the paternal allele
is unmethylated [7]. Thus, this region is called the Peg3DMR (Differentially Methylated Region). This allele-specific methylation pattern is setup during gametogenesis
and maintained throughout somatic cells [8]. This maternal-specific methylation of the Peg3-DMR is consistent
with the paternal-specific expression of the two genes.
The Peg3-DMR can be divided into two smaller regions:
the 1.3-kb promoter region containing two 1st exons and
TSSs for Peg3 and Usp29, and the 2.5-kb 1st intron region
of Peg3 (Fig. 1). The 2.5-kb 1st intron of Peg3 is known to
harbor two evolutionarily conserved sequence elements,
CSE1 and CSE2 [9]. A single copy of the 42-bp-long CSE1
is located 1-kb downstream of the 1st exon of Peg3. The relative position and orientation of CSE1 to Peg3's 1st exon
are well conserved among all the mammals tested. The Grich sequence of CSE1 is also well conserved. However,
the exact roles and binding proteins for CSE1 are currently
unknown. By contrast, many copies of the 11-bp CSE2 are
distributed over the 2.5-kb region without any obvious
pattern of location and spacing among different mammals. But the orientation of each copy of CSE2 is the same
and is conserved among different species. Similar clusters
of transcription-factor binding sites are also observed in
other imprinted domains, such as CTCF sites in H19/Igf2
and Dlk1/Gtl2 [10-12]. As seen in the CTCF sites of other
domains, the genomic region surrounding the CSE2s was
also shown to have an enhancer-blocking activity [9,13].
According to ChIP experiments, CSE2 acts as an in vivo
DNA-binding site for transcription factor YY1. YY1 binding to CSE2 is allele-specific, only to the unmethylated
paternal allele of the Peg3-DMR. Subsequent siRNA-based
YY1 knockdown experiments further demonstrated the
involvement of YY1 in the DNA methylation and transcriptional control of the Peg3-DMR [14,15]. Nevertheless, it is still unclear if and how CSE2 (YY1 binding sites)
are directly involved in the transcriptional control and
other related roles of the Peg3-DMR.
The two conserved elements, CSE1 and CSE2, are likely to
have functional roles in both genomic imprinting and
transcription of the two neighbor genes, Peg3 and Usp29.
In the current study, we sought to characterize these two
elements in terms of their possible roles in transcriptional
control for Peg3 and Usp29 using in vitro reporter assay
systems. We performed several series of mutagenesis
experiments and analyzed the effects of these mutations
on the transcriptional activity of the Peg3-DMR. Accord-
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ing to the results, CSE2 (YY1 binding sites) functions as an
orientation-dependent transcriptional activator for the
Peg3 transcription, whereas CSE1 acts as an orientationdependent repressor for the transcription of both Peg3
and Usp29.

Results
CSE2 (YY1 binding sites) as a transcriptional activator
To analyze the functional roles of CSE2 (YY1 binding
sites) in the transcriptional activity of the Peg3-DMR, we
have generated a series of 10 different constructs by modifying and subcloning the 3.8-kb endogenous region of
the mouse Peg3-DMR containing 6 YY1 binding sites into
a promoterless reporter system, IRES-β-Geo (Fig. 1). Each
of these constructs differs from the others by the orientation and number of YY1 binding sites. The orientation of
the YY1 binding sites was reversed by subcloning the 2.5kb YY1 binding region in the opposite orientation relative
to the endogenous genomic region of the Peg3-DMR
(Constructs named as -YR). To mutate the 6 YY1 binding
sites of mouse Peg3-DMR, three bases located within the
core motif of each YY1 binding site were changed from
GGCGCCATCTT to GGCATTATCTT (Constructs named
as -mY). This mutagenesis experiment was also performed
serially on each of the YY1 binding sites starting from the
one located on the 5'-side to the one on the 3'-side, resulting in a series of the fragments containing the different
numbers of YY1 binding sites (Constructs named as 1
mYF to 6 mYF in Fig. 1B). These constructs were individually transfected into three different cell lines, HeLa,
NIH3T3 and Neuro2A, along with the internal control
luciferase vector (pGL3 control) in order to normalize the
β-gal activity.

The first series of experiments was conducted as shown in
Fig. 1A. In this series, the normalized transcriptional activity of each construct was compared to the activity of the
construct 1+C, which contains the 1.3-kb genomic region
spanning from the promoter to the CSE1 region of Peg3.
As compared to the promoter activity of Construct 1+C,
the inclusion of the 2.5-kb YY1 binding region in the forward direction resulted in a 1.7-fold increase (Construct
1+C+YF), but not when it was included in the reverse
direction (Construct 1+C+YR). This suggests that the
observed boosting effect of the 2.5-kb YY1 binding region
is orientation-dependent. The constructs containing
mutated YY1 binding sites showed a dramatic decrease in
the promoter activity of Peg3 in both directions (Construct 1+C+mYF or 1+C+mYR). There are only 18 base differences (3 base changes per YY1 binding site × 6 YY1
binding sites) between Construct 1+C+YF and Construct
1+C+mYF. Yet, these targeted mutations on 6 YY1 binding
sites completely abrogated the original increase in activity
that was caused by the inclusion of the 2.5-kb YY1 binding region. Also, the direction of the mutated YY1 binding
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Figure
CSE2
(YY1
1 binding sites) functions as a transcriptional activator
CSE2 (YY1 binding sites) functions as a transcriptional activator. The top panel shows the genomic layout of the
mouse Peg3-DMR along with the two evolutionarily conserved sequence elements, the CSE1 (open square) and the YY1 binding sites (open oval). The thick vertical lines indicate the positions of the 1st and 2nd exons of Peg3. Each of the constructs differs
from the others by the orientation and number of YY1 binding sites: the intact versus mutated YY1 binding sites (-Y or -mY),
the orientation of the YY1 binding sites (-F or -R), and the numbers of mutated YY1 binding sites (-1 mY to -6 mY) (A&B).
Black ovals represent mutated YY1 binding sites. The promoter activity of each construct was analyzed more than three times,
and the averaged value was derived along with S.D. (Standard Deviation). The averaged value for each construct was further
compared with that of the reference constructs. The two sets of promoter assays were conducted at two different times with
two different reference constructs: Construct 1+C (A) and Construct 1+C+YF (B). In order to compare the results from
these two different series, the averaged value for the reference construct (1+C+YF) of the second set was adjusted to 1.7
since the same construct derived the 1.7 fold relative to the reference construct (1+C) of the first set. These promoter assays
were performed using three different cell lines, Neuro2A, NIH3T3, and HeLa. Only the result set from the Neuro2A cell line
is shown in the graph since the other two result sets derived from NIH3T3 and HeLa cells showed almost identical patterns
[see Additional file 1].

sites did not have any major effect on activity (Constructs
1+C+mYF and 1+C+mYR) although the opposite direction somewhat reduced the activity. However, this reduction was not observed consistently in other cell lines [see
Additional file 1]. Therefore, the above results suggest that
the increased transcriptional activity caused by the 2.5-kb

YY1 binding region is mainly derived from these 6 YY1
binding sites.
The second series of experiments was performed to test
the effects of different numbers of YY1 binding sites on
the transcriptional activity of the Peg3-DMR (Fig. 1B). In
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this series, the normalized transcriptional activities of all
the constructs were compared to the activity of the construct 1+C+YF, which contains 6 intact YY1 binding sites.
The value for this control construct was adjusted to 1.7,
which is the estimated value from the first series, in order
to compare the different values derived from the two different series (Fig. 1A and 1B). As shown in Fig. 1B, the
transcriptional activities of all constructs decreased as
compared to that of the construct 1+C+YF. The mutations
on the first three YY1 binding sites resulted in about 30%
reduction in the activity (1+C+1 mYF, +2 mYF, +3 mYF),
and the mutations on two additional YY1 sites further
decreased the activity (1+4 mYF and +5 mYF). The
observed decrease in the transcriptional activity of the
Peg3-DMR is somewhat gradual but not proportional to
the reduction in the number of YY1 binding sites. In particular, the final mutation construct (1+C+6 mYF with no
YY1 sites) reversed this overall decreasing pattern with the
activity about 80% of the control vector (1+C+YF). This
suggests that each of the YY1 binding sites might have different levels of contribution and/or even different roles.
The results presented in Fig. 1B are derived from IRES-βGeo, but another set of results derived from the more sensitive IRES-Luciferase system also derived an almost identical pattern (data not shown). In sum, the above results
demonstrated the YY1 binding sites as a transcriptional
activator for the Peg3-DMR, and further suggest that each
of the YY1 binding sites may have slightly different levels
of contribution and/or role for the overall transcriptional
activity of the Peg3-DMR.
The above results were consistently observed from three
different cell lines that have been used for these promoter
assays. We are providing the results from HeLa and
NIH3T3 [see Additional file 1]. The above sets of experiments were also repeated to test the potential roles of
CSE2 in the Usp29 direction. However, we were not able
to detect any transcriptional activity of the bidirectional
promoter in the Usp29 direction (data not shown).
CSE2 (YY1 binding sites) not as an enhancer blocker
Since the genomic region surrounding YY1 binding sites
was initially shown to have an insulator (enhancer-blocking) activity, we performed a series of follow-up studies to
test if YY1 binding sites are also responsible for this insulator activity [9]. Although the YY1 sites are proven to be
an enhancer for Peg3, an immediate neighbor gene, it is
also possible that YY1 sites may function as an insulator
for other distantly located imprinted genes, such as Zim1
and Zim2, which has been often seen in other imprinted
domains. For this series of analysis, we used an original
800-bp DNA fragment derived from human PEG3-DMR,
which was used for our initial study [9]. This initial 800bp fragment of human PEG3-DMR, hYY1-1, was further
divided into 4 smaller fragments with approximately 200-
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bp size in length, hYY1-a through -d (Fig. 2). Two potential YY1 binding sites (GGCGCCATCTT) are located
within the first fragment, hYY1-a. The four small fragments were individually analyzed in both orientations for
the insulator assay. Among the four small fragments, the
second fragment, hYY1-b, showed the most significant
and consistent insulator activity, while hYY1-a and hYY1c also showed some insulator activity but much less than
that of hYY1-b. The fourth fragment, hYY1-d, showed
almost no insulator activity (data not shown). To further
determine the potential involvement of YY1 in the original insulator activity, we mutated the two YY1 binding
sites located within the 200-bp sequence of hYY1-a and
tested the mutational impact on the insulator activity. As
shown in Fig. 2 (hYY1-1a*F and R), mutations on the two
YY1 binding sites did not change the insulator activity in
either orientation. Also, it is important to note that the
second fragment, hYY1-b, does not contain YY1 binding
sites and yet showed the most significant insulator activity. This suggests that YY1 is not the transcription factor
responsible for the observed insulator activity, and further
that unknown regulatory elements other than YY1 might
be involved in the insulator activity of the PEG3-DMR.
CSE1 as a transcriptional repressor for Peg3-DMR
To test the potential involvement of CSE1 in the promoter
activity of the Peg3-DMR, another series of constructs
lacking CSE1 were also made and analyzed (Constructs
named without C in Fig. 3). The promoter assays with
these CSE1-deleted constructs derived a similar overall
pattern as the previous CSE1-containing constructs (Fig.
1A): an orientation-dependent transcriptional increase
caused by the YY1 binding sites. However, the increase in
transcriptional activity resulting from the inclusion of the
YY1 binding sites in these CSE1-deleted constructs was
much greater than those seen in the CSE1-containing constructs. In particular, Construct 1+YF showed 2.8 fold
increase, while Construct 1+C+YF yielded only 1.7 fold
increase. This suggests that CSE1 may function as a repressor for the Peg3-DMR. It is also noteworthy that this large
increase was observed only in Construct 1+YF, which contains the YY1 binding sites. The constructs lacking the YY1
binding sites, Construct 1 and 1+C, did not show any difference in activity. These results suggest that CSE1 may
function as a context-dependent repressor together with
an activator function of YY1 binding sites for the promoter activity of the Peg3-DMR.

We further analyzed the position and orientation-dependency of this potential repressor, CSE1, for transcriptional
activity of the Peg3-DMR (Fig. 3B). Three modified constructs were generated and subcloned into the IRES-β-Geo
promoterless vectors. The orientation of CSE1 of each
construct was reversed relative to the direction of Peg3
transcription (Constructs named -CR), and the position of
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Figure
CSE2
(YY1
2 binding sites) does not function as an enhancer blocker
CSE2 (YY1 binding sites) does not function as an enhancer blocker. In order to determine the minimal regions for
the previously reported insulator activity in human PEG3-DMR [9], the hYY1-1 fragment was further divided into 4 smaller
fragments with 200-bp size (hYY1-a through -d), and these fragments were subcloned into the pNI-CD vector to test insulator
activity. These inserts were localized between the erythroid-specific enhancer (E) and Neomycin resistance gene (Neo) that is
driven by the γ-globulin promoter. The values on the X axis of the graph indicate the fold difference of the survived colony
number in the G418 selection relative to the value of the negative control lacking any insulator, pNI-CD(AscI). The last fragment, hYY1-d, did not show any insulator activity, and thus was omitted in this figure. The two YY1 binding sites (oval) within
the first fragment, hYY1-a, were mutated and tested again, which is indicated by hYY1-a*. The mutated YY1 binding sites are
indicated by black ovals.

CSE1 was also move to the 3'-end of the Peg3-DMR (Construct named -C3'). As shown in Fig. 3B, the construct
with the reverse orientation of CSE1 (Construct
1+CR+YF) showed about 1.5 fold more activity relative to
the activity of the control (Construct 1+CF+YF). This is
similar to the initial boosting effect by the deletion of
CSE1 (1+YF in Fig. 3A), confirming the orientationdependent repressor activity of CSE1. Two constructs with
CSE1 in the 3'-end position (constructs 1+C3'F+YF &
1+C3'R+YF) showed slightly less but similar levels of
activity than the control (Construct 1+CR+YF), indicating
no major impact by changing the relative position of
CSE1 to the 3'-end of the Peg3-DMR. Thus, this series of
experiments confirms the position-independent repressor
role of CSE1. Repositioning CES1 to the 5'-end of the
Peg3-DMR was also performed, but this result set was
inconclusive mainly due to the fact that the 5'-side region
appears to be sensitive to the insertion by any random

sequences for subcloning (data not shown). In sum, the
above results revealed an orientation-dependent but
somewhat position-independent repressor role of CSE1
for the transcriptional activity of the Peg3-DMR.
Minimal regions of CSE1 for the transcriptional repression
of Peg3 and Usp29
The relative orientation and position of CSE1 are well
conserved among all the mammals, as shown with a subset of available genome sequences, including human, rhesus, chimpanzee, mouse, cow, and dog (Fig. 4A). This is
also consistent with the results observed from the previous experiments, the orientation and YY1 contextdependent nature of this element (Fig. 3). The CSE1
sequences from these species also share high levels of
sequence identity, ranging from 86% to 100%, but with a
couple of single-base insertions/deletions that are specific
to each species. However, the 42-bp-long CSE1 is pre-
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Figure
CSE1
functions
3
as a transcriptional repressor for Peg3-DMR
CSE1 functions as a transcriptional repressor for Peg3-DMR. The top panel shows the genomic layout of the mouse
Peg3-DMR containing the two evolutionarily conserved sequence elements, CSE1 (open square) and YY1 binding sites (open
oval). The thick vertical lines indicate the positions of the 1st and 2nd exons of Peg3. The transcriptional involvement of CSE1 in
mouse Peg3-DMR was analyzed using the IRES-β-Geo promoterless vector system. (A) The first series of assays were conducted with the ten individual constructs that differ by the presence/absence of CSE1 (with or without C in their names), the
intact versus mutated YY1 binding sites (-Y or -mY), and the orientation of YY1 binding sites (-F or -R). (B) The second series
of assays investigating the position- and orientation-dependency of CSE1 on the Peg3 promoter activity were conducted by
three additional constructs containing the reverse orientation of CSE1 (-CR & -C3'R) and the 3'-end position of CSE1 (-C3'F &
-C3'R). Each construct was analyzed more than three times as shown with the average value with S.D. The averaged value for
each construct was compared with that of the reference constructs, and subsequently presented in the graph as fold differences. Two sets of assays were conducted with two different reference constructs: Construct 1+C (A) and Construct
1+CF+YF (B). In order to compare the different values derived from the two different series, the value for the control construct of the second set (1+CF+YF) was adjusted to 1.7 as derived from the first set (1+C+YF). These assays were conducted
using three cell lines, Neuro2A, NIH3T3, and HeLa, and they all showed a similar pattern as the above set of assays using the
Neuro2A cell line [see Additional file 1].

dicted to be too long for a single DNA-binding protein.
Thus, we decided to further define potential minimal
regions for the observed repressor activity of CSE1. We
have performed serial mutation of 6-bp sections of CSE1
from purine to purine and from pyrimidine to pyrimidine
(G ↔ A & T ↔ C) (Fig. 4B). The Peg3-DMR containing

each mutated CSE1 was also subcloned into the IRES-βGeo promoterless vector in both directions (Constructs
Cmut1 to Cmut7). The constructs named with F- are positioned in the Peg3 direction (Fig. 4C), whereas the constructs with R- are in the Usp29 direction (Fig. 4D). These
constructs were analyzed in a similar manner as above.
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Figure 4regions within the CSE1 responsible for transcriptional repression of Peg3 and Usp29
Minimal
Minimal regions within the CSE1 responsible for transcriptional repression of Peg3 and Usp29. (A) Evolutionary
conservation of the CSE1 is demonstrated through aligning the sequences derived from six mammals: human, rhesus, chimpanzee, mouse, cow, and dog. The bases in red indicate differences from the human CSE1. The hyphens (-) indicate insertions/
deletions. (B) A series of 6-bp-segments were mutated on the mouse CSE1 starting from 5' to the 3'-ends. The intact sequence
of the mouse CSE1 is shown on top and the following sequences represent the mutated versions of the CSE1 with the changed
bases marked in blue. (C&D) The mutated CSE1 was analyzed for the promoter activity after subcloning into the IRES-β-Geo
promoterless vector system. The Peg3-DMR promoter containing a series of mutated CSE1 sequences was analyzed in two different directions: Peg3 (C) and Usp29 (D) directions. The construct layout on the top region of each graph shows the transcriptional direction of the mouse Peg3-DMR containing CSE1 (open square) and YY1 binding sites (open oval). The thick
vertical lines indicate the positions of the 1st exons of Peg3 and Usp29. Each construct was analyzed more than three times.
The averaged value for each construct was first compared with that of the reference construct, in this case Construct
1+C+YF, and the subsequent fold difference was presented with S.D. in the graph. These assays were conducted using two cell
lines, Neuro2A and HeLa. The result set shown in the graph was derived from Neuro2A cells but the result set from HeLa
cells also showed very similar patterns [see Additional file 1].

In the Peg3 direction, we used two controls: the intact
Peg3-DMR (Construct 1+C+YF) and the deletion Peg3DMR lacking CSE1 (Construct 1+YF). As shown in Fig. 4C,
most of the CSE1-mutated constructs showed a slightly
lower but similar activity to that of the intact control
(Construct 1+C+YF), indicating no major or only marginal effect. However, one construct (FCmut5) showed
higher activity than the intact control (Construct
1+C+YF), but similar to the deletion control (Construct
1+YF). This indicates that the 6-bp region mutated within

Construct FCmut5 may be solely responsible for the original effect caused by the deletion of the entire region of
CSE1 (Fig. 3A). A similar series of experiments was also
performed for the Usp29 direction (Fig. 4D). Three controls were also used for this series: Construct 1+C+YF for
the comparison between the Peg3 and Usp29 directions,
and Construct R1+C+YF (the intact Peg3-DMR) and Construct R1+YF (the deletion Peg3-DMR lacking CSE1). As
shown in Fig. 4D, the overall transcriptional activity of the
Peg3-DMR is much lower in the Usp29 direction than in
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the Peg3 direction (Constructs 1+C+YF vs R1+C+YF). This
is true for most of the tested constructs, including the
CSE1-mutated constructs as well as the two control constructs (R1+C+YF and R1+YF). Nevertheless, the deletion
of CSE1 increased the transcriptional activity based on the
observed difference between the two control constructs
(R1+C+YF vs R1+YF). This may be an indication that CSE1
still be a potential repressor for the Usp29 direction. Interestingly, however, one construct (RCmut1) derived much
higher levels of activity than the deletion construct
(R1+YF). This is unusual since we have not detected this
much transcriptional activity in the Usp29 direction using
any modified construct derived from the Peg3-DMR.
Although this unusual increase requires further investigation, this may represent another critical minimal region
for the repression in the Usp29 direction. In sum, the
above results indicate that CSE1 may function as a repressor for both directions, Peg3 and Usp29, and also that one
minimal region is critical for the Peg3 direction.

Discussion
The results present in the current study demonstrate YY1
binding sites (CSE2) as an orientation-dependent activator for the Peg3 transcription, and CSE1 as a repressor for
Peg3 and Usp29 transcription. In addition, two 6-bp minimal regions have been identified within CSE1, one of
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which most likely plays a critical role for the transcriptional repression in the Peg3 direction.
The potential roles of two conserved sequence elements in
the transcriptional control of Peg3 and Usp29 could be
summarized as depicted in Fig. 5. In the Peg3 direction
(Fig. 5A), the YY1 binding sites (CSE2) function as an activator while the CSE1 as a repressor for the Peg3-DMR
bidirectional promoter. One recent independent study
also reported a similar observation but with much less
details, highlighting the potential roles of CSE1 and CSE2
for Peg3 transcription [16]. The activator role of the CSE2
is orientation-dependent and also somewhat dosagedependent based on the detection of a gradual decrease in
the transcriptional activity of the Peg3-DMR in proportion
to the reduction in the numbers of YY1 binding sites (Fig.
1). The repressor role of the CSE1 is also orientationdependent, but somewhat position-independent (Fig. 3).
It is important to note that the repressor role of the CSE1
is only detectible when the YY1 binding sites are present
nearby the CSE1. This suggests the presence of a functional, but potential antagonistic, interaction between the
two conserved sequence elements, CSE1 and CSE2. In the
Usp29 direction (Fig. 5B), the functional roles of two elements are not easily discernible mainly due to the very
low levels of the activity with in vitro reporter assay systems. Thus, the role of the CSE2 in the Usp29 direction is

Potential
Figure 5roles of CSE1 and CSE2 for transcriptional regulation of the Peg3 and Usp29
Potential roles of CSE1 and CSE2 for transcriptional regulation of the Peg3 and Usp29. Arrows indicate the transcriptional directions of Peg3 and Usp29, and their size and thickness represent the transcriptional strength of Peg3 and Usp29.
Smaller rectangles indicate seven individual sections within CSE1 that have been individually mutated. The mutated section is
marked with a black rectangle. Open and black ovals indicate intact and mutated YY1 binding sites, respectively. In the Peg3
direction (A), the YY1 binding sites (CSE2) function as activators, whereas CSE1 acts as a repressor for the Peg3 transcription.
In the Usp29 direction (B), the functional contribution of the YY1 binding sites is unknown, but CSE1 most likely plays a repressor role for Usp29 transcription.
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currently unknown. On the other hand, the deletion of
the CSE1 derived low but consistent levels of increase in
the transcriptional activity of the Peg3-DMR in the Usp29
direction, suggesting that the CSE1 might also be a repressor for the Usp29 direction (Fig. 4B). Furthermore, mutation on one minimal region within the CSE1 showed a
dramatic increase in the transcriptional activity, which is
higher than the levels of the deletion construct lacking the
entire the CSE1 region. This could be an artifact stemming
from a serendipitous sequence context generated by mutagenesis experiments, but it could also be a genuine effect
reflecting the in vivo role of this minimal region. One possible scenario would be that the CSE1 might bind two
proteins: one protein with a repressor role bind the first 6bp minimal region while the other protein with an activator role bind the other minimal region within the CSE1.
In that situation, complete deletion would not dramatically increase the transcriptional activity as seen in Construct R1+YF, but mutation of the first 6-bp region would
relieve the repression and allow the second protein to activate the transcription in the Usp29 direction (Construct
RCmut1). Overall, the two cis-elements, CSE1 and CSE2,
appear to function as a repressor and activator, respectively, for the bidirectional promoter of the Peg3-DMR.
The identification of CSE1 as a repressor is unexpected
since the expression patterns and levels of both human
and mouse PEG3 appear to be ubiquitous and very high
compared to those of other genes. Then, what could be
biological roles of this unexpected repressor, CSE1, for the
PEG3 expression? Two scenarios are possible based on all
the observations drawn from previous studies. First, CSE1
may be a cell type-specific repressor. Despite high levels of
the expression of PEG3 in the adult brains of human and
mouse, in situ hybridization results clearly demonstrated
that the spatial expression of PEG3 is limited only to a
subset of neuronal cells, including cerebellar Purkinje and
cerebral pyramidal cells, but not to the other cells, such as
cerebellar granule cells [2,3]. CSE1 could be involved in
this cell type-specific expression of PEG3 in neuronal cells.
Second, CSE1 may be a repressor responding to unknown
molecular signals for cellular and developmental pathways. According to previous studies, it has been shown
that the expression levels of human PEG3 are up-regulated
by the onset of the p53-mediated apoptosis [5,6]. Also,
the expression levels of PEG3 are also known to be
changed during muscle development as well as by the
hypoxia condition in rodent brain cells [17,18]. These
observations revealed dynamically changing expression
patterns of PEG3. CSE1 may be responsible, as a repressor,
for these dynamic responses of PEG3 to the various conditions and challenges that are faced by normal cells. The
above two possibilities remain to be investigated in the
near future, but the identification of CSE1 as a repressor
provides a new direction for the functional study of PEG3.
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In contrast to CSE1, the identification of CSE2 (YY1 binding sites) as a transcriptional activator has been expected
based on the results derived from previous studies, revealing that similar clusters of YY1 binding sites show an orientation-dependent increase in their transcriptional
activity [13]. The current study confirmed, more clearly
and precisely, this predicted role of CSE2 through targeted
mutations on YY1 binding sites (Fig. 1). However, the
activator role of CSE2 is somewhat contradictory to the
previous observations derived from siRNA-based YY1
knockdown experiments [14,15]. YY1 is predicted to be a
repressor based on the observed up-regulation of Peg3 and
Usp29 against lowering the cellular levels of YY1 protein.
These conflicting results warrant further investigation, but
may reflect potential differences stemming from the use of
two experimental systems. Most of the promoter assays
used for this study are episome-based transient experiments, and thus may or may not reflect the in vivo role of
CSE2 in chromosomal contexts. On the other hand, the
effects observed from siRNA-based YY1 knockdown
experiments could be easily mired with indirect outcomes. Regardless of as an activator or repressor, CSE2
appears to be very unusual: multiple YY1 binding sites are
scattered over the 2.5-kb intron region without any limitations in their spacing and copy numbers. So far, we have
not seen any other cis-elements for transcription that have
such unusual patterns of evolutionary conservation and
genomic layout. These unusual features may hint at one
possibility that CSE2 is designed for some roles other than
direct contribution to transcription, such as setting up
and/or maintaining DNA methylation for the Peg3-DMR.
Consistently, mutations of the CSE2 appear to have a
much milder impact on the transcriptional activity of the
Peg3-DMR than mutations of the CSE1, suggesting that
CSE1 may be the dominant player in the transcriptional
regulation of Peg3 and Usp29. However, it is important
note that CSE1 functions in a context-dependent manner
with CSE2 (YY1 binding sites). This suggests the presence
of a potential interaction between YY1 and other
unknown factors binding to CSE1, and further that this
interaction may determine final transcription rates for
both Peg3 and Usp29.

Conclusion
Taken together, CSE2 (YY1 binding sites) functions as an
orientation-dependent transcriptional activator for the
Peg3 transcription, while CSE1 acts as a repressor for the
transcription of both Peg3 and Usp29.

Methods
Plasmids
For the promoter assay of the Peg3-DMR, we have constructed two promoterless vectors containing the IRES-βGeo (a fusion protein of β-Galactosidase and Neomycin)
and luciferase reporters, respectively. The first reporter
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construct was generated through transferring the 5.1-kb
IRES-β-Geo fragment from the pGT1.8Ires-β-geo vector
[19] into the BamHI site of pBluescript SK(-). The second
reporter, a promoterless IRES-Luciferase, was constructed
through transferring the two following fragments to
pBluescript SK(+): a HindIII-SalI fragment containing the
luciferase gene from pGL4.10 [luc2] (Promega) and a PstIEcoRV fragment containing the IRES (Internal Ribosomal
Entry Site) from pGT1.8Ires-β-geo.
The genomic fragments containing mouse Peg3-DMR
[GenBank: AF105262, AF102110–AF105905] were
amplified by PCR, and subcloned into the NotI site of the
two promoterless reporters, IRES-β-Geo and IRES-Luciferase. To delete CSE1 from the Peg3-DMR, both flanking
regions of CSE1 were individually amplified by PCR
(Maxime PCR premix kit, Intron Biotech), ligated, and
finally subcloned into the reporter vectors. Also, the relative position and orientation of CSE1 were changed
through including the CSE1 sequence as part of one of
two oligonucleotide primers for PCR. To mutate six YY1
binding sites of mouse Peg3-DMR, three bases located
within the core motif of each YY1 binding site were serially changed from GGCGCCATCTT to GGCATTATCTT.
The serial mutations of six base pairs segments of CSE1
were performed in the manner of purine to purine and
pyrimidine to pyrimidine (G ↔ A & T ↔ C). These serial
mutations were performed using the QuikChange II SiteDirected Mutagenesis Kit (Stratagene).
Promoter assay
For the promoter assays, NIH3T3 and HeLa cell lines were
grown in the DMEM medium (GibcoBRL) and the
Neuro2A cell line was maintained in the MEM medium
(GibcoBRL). Media were supplemented with 10% fetal
bovine serum and 1% antibiotic-antimycotic (GibcoBRL).
All cell lines were grown at 37°C in a humidified incubator containing 5% CO2. About 2 × 105 cells were first
plated in each well of six-well plates, and then transfected
with reporter constructs on the following day using the
GeneJuice transfection reagent (Novagen). The detailed
information for the reporter assays is as follow. Each well
was transfected with the serum-free medium containing 3
μl of GeneJuice and 1 μg of DNA (0.9 μg reporter vector +
0.1 μg pGL3 Control or pRLSV40 vectors [Promega]). Two
days after transfection, the cells were harvested, washed
with PBS, and treated with 100 μl of the lysis buffer (0.25
M Tris-HCl at pH 7.8 + 0.1% NP40) for 30 mins at 4°C.
The cellular debris derived from the lysis step was
removed by centrifugation for 10 min. For the β-galactosidase assay, 30 μl of cell lysates were mixed with the same
volume of the 2× β-galactosidase assay buffer (Promega)
in a 96-well flat-bottom clear plate (Corning). After the
incubation of the plate at 37°C, the assay was terminated
with 90 μl of 1 M sodium carbonate. Absorbance was
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measured at 405 nm using the Wallac 1420 multilabel
counter VICTOR3 (PerkinElmer). To monitor transfection
efficiency, the β-galactosidase activity was normalized
with the luciferase activity. For the luciferase assay, 20 μl
of cell lysates were combined with 100 μl of the Luciferase
assay reagent (Promega) in a 96-well flat-bottom white
plate (Corning). The Dual-Glo Luciferase Assay System
(Promega) was used for the assay of the IRES-Luciferase
vector system. To monitor transfection efficiency, the firefly luciferase activity was normalized to the Renilla luciferase activity. Luminescence was measured using the
Wallac 1420 multilabel counter VICTOR3 (PerkinElmer).
Insulator assay
DNA fragments of interest were cloned into the AscI site
of pNI-CD (generous gift from Drs. Gary Felsenfeld and
Adam West). Each fragment was cloned in both orientations. The locations of the tested DNA fragments within
human BAC CIT-470F8 [GenBank: AC006115] are hYY1a (161993/161803), hYY1-b (161802/161614), hYY1-c
(161613/161400), and hYY1-d (161439/161189). Constructs were transfected into K562 cells by electroporation
at 200 V, 1000 mF (double pulse) using a Bio-Rad Gene
Pulser II. After a 10 min recovery on ice, cells were plated
into RPMI supplemented with 10% FBS, 200 mM L-glut
and Pen/Strep. Twenty-four hours post transfection, cells
were washed and resuspended in Improved MEM zinc
option (GibcoBRL). Cells were plated into 0.3% soft agar
with 1050 μg/ml Geneticine (GibcoBRL) and incubated at
37°C for 18–21 days.
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